Global Coronavirus Vaccine Market

Coronavirus Vaccine Comprehensive Study by Application (Hospitals, Research Laboratories, Clinics), End-users (Adults, Children) Players and Region - Global Market Outlook to 2028

Coronavirus Vaccine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Coronavirus affects the respiratory tract with symptoms such as a cough, fever, and in more severe cases, difficulty breathing. This disease spreads primarily through contact with an infected person when they cough or sneeze. It also spreads when a person touches a surface or object that has virus on it then touches their eyes, nose or mouth. People who have underlying medical conditions and those over 60 years old have a higher risk of developing severe disease and death. Coronavirus vaccine is in its developing stage. It is developing by the various major players in the market. This vaccine will use to stimulate the production of antibodies and provide immunity against coronavirus.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledSerum Institute of India (India), BioNTech SE (Germany), Pfizer Inc. (United States), Gilead Sciences Inc. (United States), GlaxoSmithKline (United States), Roche Holding AG (Switzerland), Inovio Pharmaceuticals, Inc. (United States), Moderna Inc. (United States), Novavax Inc. (United States) and AbbVie Inc. (United States)


This growth is primarily driven by Increasing Number of People Affecting the Coronavirus Disease Worldwide, Spread of Coronavirus Disease Worldwide and Government Initiatives and Support for Vaccine Development.

Globally, a noticeable market trend is evident High Demand for Total Cure of Coronavirus Total Cure Treatment Major Players, such as Serum Institute of India (India), BioNTech SE (Germany), Pfizer Inc. (United States), Gilead Sciences Inc. (United States), GlaxoSmithKline (United States), Roche Holding AG (Switzerland), Inovio Pharmaceuticals, Inc. (United States), Moderna Inc. (United States), Novavax Inc. (United States) and AbbVie Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
Recently Serum Institute of India, the world's largest vaccine maker announced that it is producing 40 million units of a coronavirus vaccine on trial in Oxford, without yet knowing if it works.
Recently, Oxford University’s coronavirus vaccine opens for a clinical trial on humans. The COVID-19 vaccine developed by Oxford is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein.

Influencing Trend:
High Demand for Total Cure of Coronavirus Total Cure Treatment

Market Growth Drivers:
Increasing Number of People Affecting the Coronavirus Disease Worldwide, Spread of Coronavirus Disease Worldwide and Government Initiatives and Support for Vaccine Development

Challenges:
Huge Investment for Research and Development of Coronavirus Vaccine

Restraints:
Unavailability of Government Approved Vaccines in the Market

Opportunities:
Huge Investment by Major Players for Coronavirus Vaccine Development, Rising Demand from End-users and High Future Demand for Vaccine from the Market

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Coronavirus Vaccine Market
- Analysis about New Entrants in Coronavirus Vaccine Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Coronavirus Vaccine Study Sheds Light on
— The Coronavirus Vaccine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Coronavirus Vaccine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Coronavirus Vaccine industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Research Laboratories
  • Clinics
By End-users
  • Adults
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of People Affecting the Coronavirus Disease Worldwide
      • 3.2.2. Spread of Coronavirus Disease Worldwide
      • 3.2.3. Government Initiatives and Support for Vaccine Development
    • 3.3. Market Challenges
      • 3.3.1. Huge Investment for Research and Development of Coronavirus Vaccine
    • 3.4. Market Trends
      • 3.4.1. High Demand for Total Cure of Coronavirus Total Cure Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Coronavirus Vaccine, by Application, End-users and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Coronavirus Vaccine (Value)
      • 5.2.1. Global Coronavirus Vaccine by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Research Laboratories
        • 5.2.1.3. Clinics
      • 5.2.2. Global Coronavirus Vaccine by: End-users (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Children
      • 5.2.3. Global Coronavirus Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Coronavirus Vaccine (Volume)
      • 5.3.1. Global Coronavirus Vaccine by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Research Laboratories
        • 5.3.1.3. Clinics
      • 5.3.2. Global Coronavirus Vaccine by: End-users (Volume)
        • 5.3.2.1. Adults
        • 5.3.2.2. Children
      • 5.3.3. Global Coronavirus Vaccine Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Coronavirus Vaccine (Price)
  • 6. Coronavirus Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Serum Institute of India (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioNTech SE (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gilead Sciences Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Inovio Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Moderna Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novavax Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Coronavirus Vaccine Sale, by Application, End-users and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Coronavirus Vaccine (Value)
      • 7.2.1. Global Coronavirus Vaccine by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Research Laboratories
        • 7.2.1.3. Clinics
      • 7.2.2. Global Coronavirus Vaccine by: End-users (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Children
      • 7.2.3. Global Coronavirus Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Coronavirus Vaccine (Volume)
      • 7.3.1. Global Coronavirus Vaccine by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Research Laboratories
        • 7.3.1.3. Clinics
      • 7.3.2. Global Coronavirus Vaccine by: End-users (Volume)
        • 7.3.2.1. Adults
        • 7.3.2.2. Children
      • 7.3.3. Global Coronavirus Vaccine Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Coronavirus Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Coronavirus Vaccine: by Application(USD Million)
  • Table 2. Coronavirus Vaccine Hospitals , by Region USD Million (2017-2022)
  • Table 3. Coronavirus Vaccine Research Laboratories , by Region USD Million (2017-2022)
  • Table 4. Coronavirus Vaccine Clinics , by Region USD Million (2017-2022)
  • Table 5. Coronavirus Vaccine: by End-users(USD Million)
  • Table 6. Coronavirus Vaccine Adults , by Region USD Million (2017-2022)
  • Table 7. Coronavirus Vaccine Children , by Region USD Million (2017-2022)
  • Table 8. South America Coronavirus Vaccine, by Country USD Million (2017-2022)
  • Table 9. South America Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 10. South America Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 11. Brazil Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 12. Brazil Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 13. Argentina Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 14. Argentina Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 15. Rest of South America Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 16. Rest of South America Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 17. Asia Pacific Coronavirus Vaccine, by Country USD Million (2017-2022)
  • Table 18. Asia Pacific Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 19. Asia Pacific Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 20. China Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 21. China Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 22. Japan Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 23. Japan Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 24. India Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 25. India Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 26. South Korea Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 27. South Korea Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 28. Taiwan Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 29. Taiwan Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 30. Australia Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 31. Australia Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 32. Rest of Asia-Pacific Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 33. Rest of Asia-Pacific Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 34. Europe Coronavirus Vaccine, by Country USD Million (2017-2022)
  • Table 35. Europe Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 36. Europe Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 37. Germany Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 38. Germany Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 39. France Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 40. France Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 41. Italy Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 42. Italy Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 43. United Kingdom Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 44. United Kingdom Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 45. Netherlands Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 46. Netherlands Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 47. Rest of Europe Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 48. Rest of Europe Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 49. MEA Coronavirus Vaccine, by Country USD Million (2017-2022)
  • Table 50. MEA Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 51. MEA Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 52. Middle East Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 53. Middle East Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 54. Africa Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 55. Africa Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 56. North America Coronavirus Vaccine, by Country USD Million (2017-2022)
  • Table 57. North America Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 58. North America Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 59. United States Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 60. United States Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 61. Canada Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 62. Canada Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 63. Mexico Coronavirus Vaccine, by Application USD Million (2017-2022)
  • Table 64. Mexico Coronavirus Vaccine, by End-users USD Million (2017-2022)
  • Table 65. Coronavirus Vaccine Sales: by Application(K Units)
  • Table 66. Coronavirus Vaccine Sales Hospitals , by Region K Units (2017-2022)
  • Table 67. Coronavirus Vaccine Sales Research Laboratories , by Region K Units (2017-2022)
  • Table 68. Coronavirus Vaccine Sales Clinics , by Region K Units (2017-2022)
  • Table 69. Coronavirus Vaccine Sales: by End-users(K Units)
  • Table 70. Coronavirus Vaccine Sales Adults , by Region K Units (2017-2022)
  • Table 71. Coronavirus Vaccine Sales Children , by Region K Units (2017-2022)
  • Table 72. South America Coronavirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 73. South America Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 74. South America Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 75. Brazil Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 76. Brazil Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 77. Argentina Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 78. Argentina Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 79. Rest of South America Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 80. Rest of South America Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 81. Asia Pacific Coronavirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 82. Asia Pacific Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 83. Asia Pacific Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 84. China Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 85. China Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 86. Japan Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 87. Japan Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 88. India Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 89. India Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 90. South Korea Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 91. South Korea Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 92. Taiwan Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 93. Taiwan Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 94. Australia Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 95. Australia Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 96. Rest of Asia-Pacific Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 97. Rest of Asia-Pacific Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 98. Europe Coronavirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 99. Europe Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 100. Europe Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 101. Germany Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 102. Germany Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 103. France Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 104. France Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 105. Italy Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 106. Italy Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 107. United Kingdom Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 108. United Kingdom Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 109. Netherlands Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 110. Netherlands Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 111. Rest of Europe Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 112. Rest of Europe Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 113. MEA Coronavirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 114. MEA Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 115. MEA Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 116. Middle East Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 117. Middle East Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 118. Africa Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 119. Africa Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 120. North America Coronavirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 121. North America Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 122. North America Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 123. United States Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 124. United States Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 125. Canada Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 126. Canada Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 127. Mexico Coronavirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 128. Mexico Coronavirus Vaccine Sales, by End-users K Units (2017-2022)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Coronavirus Vaccine: by Application(USD Million)
  • Table 140. Coronavirus Vaccine Hospitals , by Region USD Million (2023-2028)
  • Table 141. Coronavirus Vaccine Research Laboratories , by Region USD Million (2023-2028)
  • Table 142. Coronavirus Vaccine Clinics , by Region USD Million (2023-2028)
  • Table 143. Coronavirus Vaccine: by End-users(USD Million)
  • Table 144. Coronavirus Vaccine Adults , by Region USD Million (2023-2028)
  • Table 145. Coronavirus Vaccine Children , by Region USD Million (2023-2028)
  • Table 146. South America Coronavirus Vaccine, by Country USD Million (2023-2028)
  • Table 147. South America Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 148. South America Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 149. Brazil Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 150. Brazil Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 151. Argentina Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 152. Argentina Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 153. Rest of South America Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 154. Rest of South America Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 155. Asia Pacific Coronavirus Vaccine, by Country USD Million (2023-2028)
  • Table 156. Asia Pacific Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 157. Asia Pacific Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 158. China Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 159. China Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 160. Japan Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 161. Japan Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 162. India Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 163. India Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 164. South Korea Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 165. South Korea Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 166. Taiwan Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 167. Taiwan Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 168. Australia Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 169. Australia Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 170. Rest of Asia-Pacific Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 171. Rest of Asia-Pacific Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 172. Europe Coronavirus Vaccine, by Country USD Million (2023-2028)
  • Table 173. Europe Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 174. Europe Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 175. Germany Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 176. Germany Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 177. France Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 178. France Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 179. Italy Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 180. Italy Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 181. United Kingdom Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 182. United Kingdom Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 183. Netherlands Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 184. Netherlands Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 185. Rest of Europe Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 186. Rest of Europe Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 187. MEA Coronavirus Vaccine, by Country USD Million (2023-2028)
  • Table 188. MEA Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 189. MEA Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 190. Middle East Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 191. Middle East Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 192. Africa Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 193. Africa Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 194. North America Coronavirus Vaccine, by Country USD Million (2023-2028)
  • Table 195. North America Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 196. North America Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 197. United States Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 198. United States Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 199. Canada Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 200. Canada Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 201. Mexico Coronavirus Vaccine, by Application USD Million (2023-2028)
  • Table 202. Mexico Coronavirus Vaccine, by End-users USD Million (2023-2028)
  • Table 203. Coronavirus Vaccine Sales: by Application(K Units)
  • Table 204. Coronavirus Vaccine Sales Hospitals , by Region K Units (2023-2028)
  • Table 205. Coronavirus Vaccine Sales Research Laboratories , by Region K Units (2023-2028)
  • Table 206. Coronavirus Vaccine Sales Clinics , by Region K Units (2023-2028)
  • Table 207. Coronavirus Vaccine Sales: by End-users(K Units)
  • Table 208. Coronavirus Vaccine Sales Adults , by Region K Units (2023-2028)
  • Table 209. Coronavirus Vaccine Sales Children , by Region K Units (2023-2028)
  • Table 210. South America Coronavirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 211. South America Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 212. South America Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 213. Brazil Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 214. Brazil Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 215. Argentina Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 216. Argentina Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 217. Rest of South America Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 218. Rest of South America Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 219. Asia Pacific Coronavirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 220. Asia Pacific Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 221. Asia Pacific Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 222. China Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 223. China Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 224. Japan Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 225. Japan Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 226. India Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 227. India Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 228. South Korea Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 229. South Korea Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 230. Taiwan Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 231. Taiwan Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 232. Australia Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 233. Australia Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 234. Rest of Asia-Pacific Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 235. Rest of Asia-Pacific Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 236. Europe Coronavirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 237. Europe Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 238. Europe Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 239. Germany Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 240. Germany Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 241. France Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 242. France Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 243. Italy Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 244. Italy Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 245. United Kingdom Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 246. United Kingdom Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 247. Netherlands Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 248. Netherlands Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 249. Rest of Europe Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 250. Rest of Europe Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 251. MEA Coronavirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 252. MEA Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 253. MEA Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 254. Middle East Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 255. Middle East Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 256. Africa Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 257. Africa Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 258. North America Coronavirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 259. North America Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 260. North America Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 261. United States Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 262. United States Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 263. Canada Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 264. Canada Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 265. Mexico Coronavirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 266. Mexico Coronavirus Vaccine Sales, by End-users K Units (2023-2028)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Coronavirus Vaccine: by Application USD Million (2017-2022)
  • Figure 5. Global Coronavirus Vaccine: by End-users USD Million (2017-2022)
  • Figure 6. South America Coronavirus Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Coronavirus Vaccine Share (%), by Country
  • Figure 8. Europe Coronavirus Vaccine Share (%), by Country
  • Figure 9. MEA Coronavirus Vaccine Share (%), by Country
  • Figure 10. North America Coronavirus Vaccine Share (%), by Country
  • Figure 11. Global Coronavirus Vaccine: by Application K Units (2017-2022)
  • Figure 12. Global Coronavirus Vaccine: by End-users K Units (2017-2022)
  • Figure 13. South America Coronavirus Vaccine Share (%), by Country
  • Figure 14. Asia Pacific Coronavirus Vaccine Share (%), by Country
  • Figure 15. Europe Coronavirus Vaccine Share (%), by Country
  • Figure 16. MEA Coronavirus Vaccine Share (%), by Country
  • Figure 17. North America Coronavirus Vaccine Share (%), by Country
  • Figure 18. Global Coronavirus Vaccine share by Players 2022 (%)
  • Figure 19. Global Coronavirus Vaccine share by Players (Top 3) 2022(%)
  • Figure 20. Global Coronavirus Vaccine share by Players (Top 5) 2022(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 23. Serum Institute of India (India) Revenue: by Geography 2022
  • Figure 24. BioNTech SE (Germany) Revenue, Net Income and Gross profit
  • Figure 25. BioNTech SE (Germany) Revenue: by Geography 2022
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Gilead Sciences Inc. (United States) Revenue: by Geography 2022
  • Figure 30. GlaxoSmithKline (United States) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline (United States) Revenue: by Geography 2022
  • Figure 32. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 34. Inovio Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Inovio Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Moderna Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Moderna Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Novavax Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Novavax Inc. (United States) Revenue: by Geography 2022
  • Figure 40. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 42. Global Coronavirus Vaccine: by Application USD Million (2023-2028)
  • Figure 43. Global Coronavirus Vaccine: by End-users USD Million (2023-2028)
  • Figure 44. South America Coronavirus Vaccine Share (%), by Country
  • Figure 45. Asia Pacific Coronavirus Vaccine Share (%), by Country
  • Figure 46. Europe Coronavirus Vaccine Share (%), by Country
  • Figure 47. MEA Coronavirus Vaccine Share (%), by Country
  • Figure 48. North America Coronavirus Vaccine Share (%), by Country
  • Figure 49. Global Coronavirus Vaccine: by Application K Units (2023-2028)
  • Figure 50. Global Coronavirus Vaccine: by End-users K Units (2023-2028)
  • Figure 51. South America Coronavirus Vaccine Share (%), by Country
  • Figure 52. Asia Pacific Coronavirus Vaccine Share (%), by Country
  • Figure 53. Europe Coronavirus Vaccine Share (%), by Country
  • Figure 54. MEA Coronavirus Vaccine Share (%), by Country
  • Figure 55. North America Coronavirus Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Serum Institute of India (India)
  • BioNTech SE (Germany)
  • Pfizer Inc. (United States)
  • Gilead Sciences Inc. (United States)
  • GlaxoSmithKline (United States)
  • Roche Holding AG (Switzerland)
  • Inovio Pharmaceuticals, Inc. (United States)
  • Moderna Inc. (United States)
  • Novavax Inc. (United States)
  • AbbVie Inc. (United States)
Select User Access Type

Key Highlights of Report


Sep 2023 226 Pages 76 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Coronavirus Vaccine Market Quantitative research analysis
Global Coronavirus Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Coronavirus Vaccine market are Serum Institute of India (India), BioNTech SE (Germany), Pfizer Inc. (United States), Gilead Sciences Inc. (United States), GlaxoSmithKline (United States), Roche Holding AG (Switzerland), Inovio Pharmaceuticals, Inc. (United States), Moderna Inc. (United States), Novavax Inc. (United States) and AbbVie Inc. (United States), to name a few.
is dominating the Coronavirus Vaccine Market.
"Huge Investment for Research and Development of Coronavirus Vaccine" is seen as one of the major challenges by many Industry Players of Coronavirus Vaccine Market
The Coronavirus Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Coronavirus Vaccine market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Coronavirus Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Fluvastatin Sodium Drug Comprehensive Study by Type (Tablets, Capsules), Application (Cardiovascular Disease, Plasma Cholesterol Levels), Distribution Channel (Online, Offline), End-User (Hospital Ph...
$ 3350
Hydroxychloroquine Comprehensive Study by Type (Hydroxychloroquine 200 mg, Hydroxychloroquine 300 mg, Hydroxychloroquine 400 mg), Application (Lupus Erythematosus, Rheumatoid Arthritis, COVID-19, Oth...
$ 3650
Cervical Cancer Vaccines Comprehensive Study by Type (Gardasil, Gardasil 9, Cervarix), Application (Prostate cancer, Cervical cancer, Other), Distribution Channel (Hospitals, Clinics, Others), Treatm...
$ 3450
Pharma E-commerce Comprehensive Study by Type (Rx (prescription medicine), OTC (over the counter)), Application (Individual Use, Industrial Use) Players and Region - Global Market Outlook to 2028
$ 3500
Medical Packaging Solutions Comprehensive Study by Type (-Primary Packaging, Blister Pack, Pouches, Bottles & Container, Others, -Secondary Packaging, Folding Cartons, Paperboard, Trays, Others, -Ter...
$ 3450
Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, ...
$ 3450